Limitless Potential.
Precision Design.
Enduring Impact.
Aiming to transform treatment of cancer and autoimmune diseases by developing allogeneic, iPSC-derived NK and T cell therapies.
PRESS RELEASES + EVENTS
view all
April 15, 2025
Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025
PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative…
March 19, 2025
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led…
About us
We are building an industry leading allogeneic iPSC-derived cell therapy platform for cancer and autoimmune diseases.
OUR SCIENCE
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.
